Mobia Medical Announces Publication of Two-Year Data from VNS-REHAB Trial Demonstrating Durable and Continued Stroke Recovery with Vivistim® Paired VNS™ Therapy
Mobia Medical (Nasdaq: MOBI) said Neurology published two-year follow-up results from its VNS-REHAB trial of Vivistim Paired VNS Therapy in chronic ischemic stroke. Among 49 participants, 76% met response on FMA-UE and/or WMFT, with average gains of +7.5 FMA-UE and +0.63 WMFT. Mobia reported improvements in daily living and quality of life sustained for at least two years.
How this was made
The 30-second read
Why it matters
The two-year Neurology publication reports sustained improvements in upper-limb motor impairment/function and patient-reported daily living and quality-of-life measures, reinforcing durability of benefit after in-clinic therapy completion.
Market read
For MOBI, the incremental value is the peer-reviewed, two-year durability dataset with quantified responder rates and improvements on FMA-UE and WMFT, plus patient-reported quality-of-life gains.
What to watch
The article does not provide safety details beyond 'no long-term serious adverse events' or discuss effect sizes versus controls at two years, limiting how much incremental conviction the market can gain from this release alone.
Background
Mobia’s Vivistim Paired VNS Therapy received FDA premarket approval in 2021, with pivotal VNS-REHAB results previously published in The Lancet and one-year follow-up reported in Stroke.
Ticker impact
Mobia Medical published two-year VNS-REHAB follow-up in Neurology, reporting sustained upper-limb and daily-living improvements through year two.
Moderate positive bias for MOBI as the market digests durable efficacy data, though magnitude depends on prior expectations and any concurrent guidance/coverage updates.
This is a company-specific clinical-data milestone with multiple efficacy endpoints and no long-term serious adverse events reported through two years, but it is a publication rather than a new regulatory decision or revenue print.
Market effects
Adds to the evidence base for implantable neuromodulation in chronic ischemic stroke recovery, potentially improving perceived credibility for similar neurorehab platforms.
No clear regional catalyst beyond US-listed MOBI.
Primarily US-focused clinical evidence, but peer-reviewed publication can influence global clinician and payer discussions.
Counterpoint
Durability claims may already be partially anticipated from earlier one-year results; publication alone may not change payer behavior without new endpoints, subgroup signals, or reimbursement updates.
Key entities
- companyMobia Medical, Inc.
Nasdaq-listed medical device company commercial-stage in stroke recovery with Vivistim Paired VNS Therapy.
- clinical_trialVNS-REHAB trial
Multicenter, triple-blinded, sham-controlled randomized trial in chronic ischemic stroke evaluating Vivistim Paired VNS Therapy.
- productVivistim Paired VNS Therapy
Implantable vagus nerve stimulation paired with functional movement to promote neuroplasticity in chronic stroke recovery.
- publicationNeurology® (journal)
Peer-reviewed journal of the American Academy of Neurology where the two-year follow-up was published.
